MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Fermé

3.24 -1.22

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.18

Max

3.2800000000000002

Chiffres clés

By Trading Economics

Revenu

44M

-26M

Ventes

-5.8M

42M

Marge bénéficiaire

-61.388

Employés

550

EBITDA

44M

-22M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+29.97% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

144M

1.2B

Ouverture précédente

4.46

Clôture précédente

3.24

Score Technique

By Trading Central

Confiance

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

31 déc. 2025, 22:20 UTC

Principaux Mouvements du Marché

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31 déc. 2025, 17:31 UTC

Principaux Mouvements du Marché

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31 déc. 2025, 16:30 UTC

Principaux Mouvements du Marché

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31 déc. 2025, 15:19 UTC

Principaux Mouvements du Marché

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31 déc. 2025, 15:17 UTC

Principaux Mouvements du Marché

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31 déc. 2025, 14:37 UTC

Principaux Mouvements du Marché

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31 déc. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31 déc. 2025, 21:13 UTC

Acquisitions, Fusions, Rachats

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31 déc. 2025, 20:40 UTC

Market Talk

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31 déc. 2025, 20:22 UTC

Market Talk

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31 déc. 2025, 19:50 UTC

Market Talk

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31 déc. 2025, 19:31 UTC

Market Talk

Precious Metals Cap Off Record Runs -- Market Talk

31 déc. 2025, 18:50 UTC

Market Talk

Global Equities Roundup: Market Talk

31 déc. 2025, 18:50 UTC

Market Talk

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31 déc. 2025, 17:17 UTC

Market Talk

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31 déc. 2025, 17:16 UTC

Principaux Mouvements du Marché

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31 déc. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

31 déc. 2025, 17:00 UTC

Acquisitions, Fusions, Rachats

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31 déc. 2025, 15:57 UTC

Acquisitions, Fusions, Rachats

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31 déc. 2025, 15:54 UTC

Market Talk

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31 déc. 2025, 15:02 UTC

Principaux Mouvements du Marché

Nike Shares Rise After CEO Hill Buys $1M of Shares

31 déc. 2025, 14:40 UTC

Acquisitions, Fusions, Rachats

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31 déc. 2025, 14:20 UTC

Market Talk

Crude Futures On Track to End the Year With Losses -- Market Talk

31 déc. 2025, 13:46 UTC

Market Talk

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31 déc. 2025, 13:01 UTC

Résultats
Acquisitions, Fusions, Rachats

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31 déc. 2025, 11:10 UTC

Market Talk

Copper Remains in Touching Distance of Record Highs -- Market Talk

31 déc. 2025, 10:46 UTC

Market Talk

Euro on Track For Strong Annual Performance -- Market Talk

31 déc. 2025, 10:25 UTC

Market Talk

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31 déc. 2025, 10:23 UTC

Market Talk

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31 déc. 2025, 09:33 UTC

Market Talk

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

29.97% hausse

Prévisions sur 12 Mois

Moyen 4.25 USD  29.97%

Haut 4.5 USD

Bas 4 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

3

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

2.02 / 2.115Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat